ARVN · XBRL financial data

Arvinas financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (ARVN's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	22	47	131	79	263	263
Revenue from contracts with customers	22	47	—	—	—	—
Research and development	108	180	315	380	348	285
General and administrative	38	62	80	100	165	96
Total operating expenses	147	242	395	480	514	381
Operating income (loss)	(125)	(195)	(263)	(402)	(250)	(119)
Interest income	4	2	12	39	55	38
Interest expense	0	0	0	0	0	—
Other income (expense)	2	3	0	(1)	(3)	(0)
Income tax expense (benefit)	0	0	21	1	1	0
Net income (loss)	(119)	(191)	(283)	(367)	(199)	(81)
Earnings per share, basic USD per share	(3.02)	(3.82)	(5.31)	(6.62)	(2.77)	(1.14)
Earnings per share, diluted USD per share	(3.02)	(3.82)	(5.31)	(6.62)	(2.77)	(1.14)
Weighted average shares, basic millions of shares	40	50	53	56	72	71
Weighted average shares, diluted millions of shares	40	50	53	56	72	71

Fiscal years (ARVN's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	588	108	81	312	101	143
Marketable securities	100	1,394	1,124	949	939	543
Accounts receivable	1	15	1	0	6	1
Prepaid and other current assets	6	20	21	7	14	9
Total current assets	703	1,553	1,240	1,280	1,067	701
Property and equipment, net	12	13	13	12	7	5
Right-of-use asset	2	4	4	3	9	8
Total assets	717	1,582	1,269	1,305	1,091	718
Accounts payable	7	31	6	18	13	24
Accrued liabilities	19	23	—	—	—	—
Current portion of long-term debt	—	—	0	0	0	0
Total current liabilities	49	262	295	257	230	143
Long-term debt	2	1	1	1	1	0
Lease liability, non-current	1	3	3	1	7	7
Total liabilities	75	800	704	645	530	284
Accumulated deficit	(492)	(683)	(965)	(1,333)	(1,532)	(1,612)
Total stockholders' equity	642	782	565	660	562	434
Total liabilities and equity	717	1,582	1,269	1,305	1,091	718
Common shares outstanding (cover page) millions of shares	49	53	53	68	69	64

Fiscal years (ARVN's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(119)	(191)	(283)	(367)	(199)	(81)
Stock-based compensation	30	57	76	72	88	44
Net cash from operating activities	(90)	559	(274)	(348)	(259)	(274)
Purchases of property and equipment	6	5	7	3	2	2
Net cash from investing activities	164	(1,314)	243	204	35	408
Proceeds from issuing equity	—	1,300	—	—	—	—
Share repurchases	—	—	—	0	0	92
Proceeds from long-term debt	0	—	—	—	—	—
Repayments of long-term debt	0	0	0	0	0	0
Net cash from financing activities	505	279	5	375	8	(91)
Net change in cash	579	(476)	(26)	230	(217)	42

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Arvinas	88	0.5	(10)*	65.5M	13.0 quarters	Q3 FY26 10-QSep 30, 2026
Arbutus Biopharma	19	1	(6)*	197.8M	15.4 quarters	Q2 FY26 10-QJun 30, 2026
aTYR PHARMA	16	not reported	(9.4)*	98.1M	6.1 quarters	Q2 FY26 10-QJun 30, 2026
Zevra Therapeutics	122	38	10*	59.5M	—	Q3 FY26 10-QSep 30, 2026
Theravance Biopharma	220	21	(7)*	51.9M	55.7 quarters	Q2 FY26 10-QJun 30, 2026
Myriad Genetics	115	191	(8.3)*	95.6M	13.9 quarters	Q2 FY26 10-QJun 30, 2026
Kura Oncology	70	21	(63)*	89.0M	8.3 quarters	Q2 FY26 10-QJun 30, 2026
KalVista Pharmaceuticals	214	41	(14)	53.2M	19.7 quarters	Q1 FY26 10-QMar 31, 2026
CytoDyn	16	not reported	(7.7)	1.5B	2.1 quarters	Q1 FY27 10-QAug 31, 2026

Not investment advice. Not affiliated with the U.S. SEC.